Switch theme

🎉 M&A multiples are live!
Check it out!

Mycenax Biotech Valuation Multiples

Discover revenue and EBITDA valuation multiples for Mycenax Biotech and similar public comparables like Armata Pharmaceuticals, Vivoryon Therapeutics, and Pharming.

All Biopharmaceuticals Multiples Start Free Trial
Mycenax Biotech logo Mycenax Biotech logo

Sign up to access all valuation multiples

Mycenax Biotech Overview

About Mycenax Biotech

Mycenax Biotech Inc is a Taiwan-based biopharmaceutical company. It is engaged in the development and manufacture of biopharmaceutical products, specializing in mammalian and microbial cell-derived biologics. The company provides services for program evaluation/confirmation, cell line development, and construction, process development technology platforms, drug characterization analysis, the establishment of testing methods, and drug production in accordance with PIC/S GMP manufacturing standards.

Founded

2001

HQ

Taiwan
Employees

337

Website

mycenax.com.tw

Financials

Last FY Revenue $22.8M

Last FY EBITDA -$4.6M

EV

$293M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 12K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Mycenax Biotech Financials

In the most recent fiscal year, Mycenax Biotech achieved revenue of $22.8M and an EBITDA of -$4.6M.

Mycenax Biotech expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Mycenax Biotech valuation multiples based on analyst estimates

Mycenax Biotech P&L

NTM Last FY FY 2025 FY 2026 FY 2027
Revenue XXX $22.8M XXX XXX XXX
Gross Profit XXX -$8.1M XXX XXX XXX
Gross Margin XXX -35% XXX XXX XXX
EBITDA XXX -$4.6M XXX XXX XXX
EBITDA Margin XXX -20% XXX XXX XXX
EBIT XXX -$15.4M XXX XXX XXX
EBIT Margin XXX -67% XXX XXX XXX
Net Profit XXX -$15.6M XXX XXX XXX
Net Margin XXX -68% XXX XXX XXX
Net Debt XXX $17.0M XXX XXX XXX

Financial data powered by Morningstar, Inc.

Mycenax Biotech Stock Performance

As of May 30, 2025, Mycenax Biotech's stock price is TWD 39 (or $1).

Mycenax Biotech has current market cap of TWD 8.1B (or $269M), and EV of TWD 8.8B (or $293M).

See Mycenax Biotech trading valuation data

Mycenax Biotech Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$293M $269M XXX XXX XXX XXX n/a

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Mycenax Biotech Valuation Multiples

As of May 30, 2025, Mycenax Biotech has market cap of $269M and EV of $293M.

Mycenax Biotech's trades at 12.9x EV/Revenue multiple, and -64.4x EV/EBITDA.

Equity research analysts estimate Mycenax Biotech's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

Mycenax Biotech's P/E ratio is not available.

See valuation multiples for Mycenax Biotech and 12K+ public comps

Mycenax Biotech Financial Valuation Multiples

LTM NTM Last FY FY 2025 FY 2026 FY 2027
Market cap (current) $269M XXX $269M XXX XXX XXX
EV (current) $293M XXX $293M XXX XXX XXX
EV/Revenue n/a XXX 12.9x XXX XXX XXX
EV/EBITDA n/a XXX -64.4x XXX XXX XXX
EV/EBIT n/a XXX -19.0x XXX XXX XXX
EV/Gross Profit n/a XXX n/a XXX XXX XXX
P/E n/a XXX -17.3x XXX XXX XXX
EV/FCF n/a XXX -16.8x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Mycenax Biotech Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Mycenax Biotech Margins & Growth Rates

Mycenax Biotech's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $22K for the same period.

Mycenax Biotech's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Mycenax Biotech's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Mycenax Biotech and other 12K+ public comps

Mycenax Biotech Operational Valuation Multiples

LTM NTM Last FY FY 2025 FY 2026 FY 2027
Revenue Growth n/a XXX n/a XXX XXX XXX
EBITDA Margin n/a XXX -20% XXX XXX XXX
EBITDA Growth n/a XXX n/a XXX XXX XXX
Rule of 40 n/a XXX n/a XXX XXX XXX
Bessemer Rule of X XXX XXX n/a XXX XXX XXX
Revenue per Employee XXX XXX $0.1M XXX XXX XXX
Opex per Employee XXX XXX $22K XXX XXX XXX
S&M Expenses to Revenue XXX XXX 8% XXX XXX XXX
G&A Expenses to Revenue XXX XXX n/a XXX XXX XXX
R&D Expenses to Revenue XXX XXX 11% XXX XXX XXX
Opex to Revenue XXX XXX 32% XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms
Explore Valuation Multiples by Industry
Start Free Trial

Mycenax Biotech Public Comps

See public comps and valuation multiples for Biopharmaceuticals and Contract Research & Manufacturing comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
Armata Pharmaceuticals XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Mycenax Biotech M&A and Investment Activity

Mycenax Biotech acquired  XXX companies to date.

Last acquisition by Mycenax Biotech was  XXXXXXXX, XXXXX XXXXX XXXXXX . Mycenax Biotech acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Mycenax Biotech

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Start Free Trial

About Mycenax Biotech

When was Mycenax Biotech founded? Mycenax Biotech was founded in 2001.
Where is Mycenax Biotech headquartered? Mycenax Biotech is headquartered in Taiwan.
How many employees does Mycenax Biotech have? As of today, Mycenax Biotech has 337 employees.
Is Mycenax Biotech publicy listed? Yes, Mycenax Biotech is a public company listed on ROCO.
What is the stock symbol of Mycenax Biotech? Mycenax Biotech trades under 4726 ticker.
When did Mycenax Biotech go public? Mycenax Biotech went public in 2013.
Who are competitors of Mycenax Biotech? Similar companies to Mycenax Biotech include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics.
What is the current market cap of Mycenax Biotech? Mycenax Biotech's current market cap is $269M
Is Mycenax Biotech profitable? Yes, Mycenax Biotech is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.

Start Free Trial 🎦 Book a Call